What does OOPD stand for?

Office of Orphan Products Development (FDA)

This definition appears very rarely and is found in the following Acronym Finder categories:

Military and Government
Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Object-Oriented Programming for All (online coding library) Oregon Optometric Physicians Association Oregon Ocean Policy Advisory Council Out of Place Artifact (archeology) Object-Oriented Procedure Call (computing) Oceans Observation Panel for Climate Oleyl-Oxyethyl-Phosphoryl-Choline (enzyme) Olive Oil Phenolic Compounds (pharmacology) Out-of-Pocket Cost (finance) Object Oriented Programming and Design (software course)		Object-Oriented Programming Environment Out of Pocket Expenses (health insurance) Out of Programme Experience (training programs; UK) Office for Official Publications of the European Communities Object-Oriented Particle-in-Cell (plasma physics) Object-Oriented Programmable Integrated Circuit Object Oriented Programming Language Object Oriented Project Management Object-Oriented Programming and Models of Concurrency Out-of-Pocket Medical Expenses

Samples in periodicals archive:

Byline: pinto03 Families of Spinal Muscular Atrophy (Libertyville, IL) announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted Orphan Drug Designation to Quinazoline495 for the treatment of Spinal Muscular Atrophy.

United States : Families Of Spinal Muscular Atrophy Receives FDA ...

The United States Food and Drug Administration's Office of Orphan Products Development has granted orphan designation for Amigal in the United States, and the European Commission has designated Amigal as an orphan medicinal product in the European Union.

Amicus and Shire enter Into $440 million ex-US licensing agreement to ...

In addition, SGN-40 was granted orphan drug designation for CLL by the FDA's Office of Orphan Products Development.

SEATTLE GENETICS EXPANDS SGN-40 PROGRAM FOR LEUKEMIA

Abraxis BioScience was recently notified that the FDA's Office of Orphan Products Development (OOPD) has granted ABRAXANE with orphan drug status in the treatment of pancreatic cancer and melanoma stage IIb-IV.

Abraxis BioScience Reports 2009 Third Quarter Financial Results

a developer of leading-edge unique therapeutics for the advanced treatment of cancer, has announced that the Office of Orphan Products Development of the FDA has determined that Oncolym qualifies for orphan designation for the treatment of intermediate and high-grade B-Cell Non-Hodgkin's Lymphoma.

TECHNICLONE'S ONCOLYM QUALIFIES AS ORPHAN DRUG

Orphan drug designation, when granted by the FDA's Office of Orphan Products Development, allows for up to seven years of marketing exclusivity after gaining FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.

OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study ...

In February 2009, CytRx announced the commencement of a Phase 2/3 adaptive clinical trial, sponsored by the ALS Association and the FDA's Office of Orphan Products Development OOPD, to study arimoclomol in a subset of patients with the inherited or familial form of ALS.

CytRx Files Report with the FDA in Response to the Partial Clinical ...

The FDA Office of Orphan Products Development was very cooperative with us but we are naturally disappointed.

Advaxis Receives FDA Response to Orphan Drug Filing